Cannabidiol (CBD) has emerged as a potential anti-inflammatory compound for arthritis, interacting with the endocannabinoid system to reduce pro-inflammatory cytokines and alleviate joint swelling and pain. Preclinical models have consistently shown these effects, and emerging human data suggest translational benefits.
In a randomized controlled trial, topical CBD significantly improved pain and disability in patients with thumb basal joint arthritis, with no adverse events reported (Heineman et al., 2022). Topical formulations have also shown broader anti-inflammatory potential in human skin and tissue models, supporting their application in joint conditions.
While large-scale trials are limited, pilot human studies and systematic reviews of topical CBD indicate promise for reducing inflammation in arthritic conditions, positioning it as a non-psychoactive option worth further investigation.
References
-
Heineman, J. T., DeGeorge, B. R., & University of Virginia Department of Plastic Surgery. (2022). A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. The Journal of Hand Surgery, 47(7), 611–620. https://doi.org/10.1016/j.jhsa.2022.03.002
-
Palmieri, B., Vadala, M., & Romano, B. (2019). A therapeutic effect of CBD-enriched ointment in inflammatory skin diseases and cutaneous scars. La Clinica Terapeutica, 170(2), e93–e99. https://doi.org/10.7417/CT.2019.2116
-
Scholfield, C. N., et al. (2023). Systematic review on transdermal/topical cannabidiol trials: A reconsidered way forward. Cannabis and Cannabinoid Research, 8(4), 589–602. https://doi.org/10.1089/can.2021.0154
